advertisement
Han X 28
Showing records 1 to 25 | Display all abstracts from Han X106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Liu Q
Eye 2023; 37: 2335-2343
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Hu J
International Journal of Nanomedicine 2022; 17: 5915-5931
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Siggs OM
JAMA ophthalmology 2022; 141: 73-77
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Li H
International Journal of Nanomedicine 2022; 17: 5915-5931
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Qassim A
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Davis J
Eye 2023; 37: 2335-2343
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Han X
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Han X
Eye 2023; 37: 2335-2343
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Zhao Y
International Journal of Nanomedicine 2022; 17: 5915-5931
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Mackey DA
Eye 2023; 37: 2335-2343
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Ke Y
International Journal of Nanomedicine 2022; 17: 5915-5931
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Marshall HN
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Macgregor S
Eye 2023; 37: 2335-2343
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Rupenthal ID
International Journal of Nanomedicine 2022; 17: 5915-5931
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Mullany S; He W
JAMA ophthalmology 2022; 141: 73-77
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Liu H
International Journal of Nanomedicine 2022; 17: 5915-5931
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Craig JE
Eye 2023; 37: 2335-2343
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Souzeau E
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Si L
Eye 2023; 37: 2335-2343
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Ye J; Han X
International Journal of Nanomedicine 2022; 17: 5915-5931
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Hewitt AW
Eye 2023; 37: 2335-2343
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Galanopoulos A
JAMA ophthalmology 2022; 141: 73-77
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Yang F
International Journal of Nanomedicine 2022; 17: 5915-5931
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Agar A
JAMA ophthalmology 2022; 141: 73-77
106630 Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction
Li W
International Journal of Nanomedicine 2022; 17: 5915-5931
